Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07400523 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Name: Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy — clinical trial record (NCT07400523)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Started2026-02-10

View on ClinicalTrials.gov ↗

Amendment history

2026-04-27

Study Status, Contacts/Locations v3

Study sites3→4

2026-04-16

Study Status, Contacts/Locations v2

Study sites1→3

2026-04-12

Study Status, Contacts/Locations v1

Recruitment opened

Study sites0→1

2026-02-03

Original filing

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

247 trials monitored

See 2 trials at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

This is a multi-center, open-lable, prospective, randomized phase III clinical trial to investigate the efficacy and safety of adjuvant ribociclib combined with aromatase inhibitor in hormone receptor-positive, HER2-negative early breast cancer with residual disease after neoadjuvant chemotherapy

Trial Details

NCT Number	NCT07400523
Lead Sponsor	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions	Breast Cancer
Enrollment	446 participants
Start Date	2026-02-10
Primary Completion	2030-02-10 (estimated)
Study Completion	2031-02-10 (estimated)
Updated on ClinicalTrials.gov	2026-04-28